Guggenheim Reiterates Buy on Neumora Therapeutics, Maintains $14 Price Target
Benzinga Newsdesk 7 months ago
NewsPrice TargetReiterationAnalyst Ratings
Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $14 price target.
Guggenheim analyst Yatin Suneja reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $14 price target.